Cite
Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
MLA
Aimery de Gramont, et al. “Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy.” Clinical Cancer Research, vol. 17, Nov. 2011, pp. 7470–78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4f5420eab63fb1abecc2806176562c8a&authtype=sso&custid=ns315887.
APA
Aimery de Gramont, David Malka, Peggy Cuillière-Dartigues, Jean-François Fléjou, Philippe Rougier, Franck Bonnetain, Cedric Lecaille, Christophe Louvet, Aziz Zaanan, Guetz Gaëtan Des, Françoise Praz, Julien Taieb, Jean-François Emile, & Pierre Validire. (2011). Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clinical Cancer Research, 17, 7470–7478.
Chicago
Aimery de Gramont, David Malka, Peggy Cuillière-Dartigues, Jean-François Fléjou, Philippe Rougier, Franck Bonnetain, Cedric Lecaille, et al. 2011. “Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy.” Clinical Cancer Research 17 (November): 7470–78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4f5420eab63fb1abecc2806176562c8a&authtype=sso&custid=ns315887.